Drug intelligence / Profile preview

AL-54478

Development stage: Phase 2
Lead developer: Alcon
Modality: Small Molecules
Administration: Ophthalmic

Overview

AL-54478 is a small molecule drug that acts as an agonist of the prostanoid receptor. It was initially developed by Novartis Pharma AG and later associated with Alcon Research. The compound was investigated primarily for ophthalmic indications, specifically for the treatment of open-angle glaucoma and ocular hypertension. Its mechanism involves activation of prostanoid receptors, which are implicated in intraocular pressure regulation. Clinical development reached Phase 2 before being discontinued, and no further development or approval has been reported[1].

Targets

PTGFR (Prostaglandin F2 alpha receptor)

Beyond the preview

Go deeper on AL-54478.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on AL-54478.

Explore the full profile